Jodie Morrison joins Atlas Venture as a venture partner. Most recently, Morrison was CEO of Cadent Therapeutics.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Atlas Venture, a leading early stage venture capital firm, announced today that Jodie Morrison is joining the firm as a venture partner. Jodie will work with the Atlas team to build transformative new biotech companies.
“At Cadent Therapeutics, we built a clinical stage company that reimagined therapeutic approaches to treating neurological and psychiatric conditions,” said Morrison. “I am excited to continue working with the Atlas Venture team in building companies that will develop game-changing therapeutics for patients.”
Morrison is an accomplished executive and board member who most recently served as CEO of Cadent Therapeutics, which Atlas Venture formed and which was acquired by Novartis in 2021. Prior to Cadent, Jodie served as interim chief executive officer at Keryx Biopharmaceuticals, Inc. where she led the successful merger with Akebia Therapeutics, and as acting chief operating officer at Syntimmune which was acquired by Alexion. Before that, she served as president and chief executive officer of Tokai Pharmaceuticals, Inc. where she led the 2014 IPO and 2016 merger, and held other senior positions including chief operating officer and VP/head of clinical and program operations. Earlier in her career, Jodie held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Jodie serves on the boards of several biotech companies, and has been recognized for her leadership skills by the Boston Business Journal’s “Power 50” and “Women to Watch” awards, and WEST’s “Making a Difference” award. Jodie has dedicated herself to advocating for diversity and inclusion in the biotech industry and has served as a founding member of the Gender Diversity Initiative at MassBio, a contributing author of a 2016 industry open letter, and a leader of the CEO Forum to pivot industry efforts towards community impact.
“Jodie has proven herself to be an incredibly effective and impactful leader throughout her career, both for the companies she has served and the biotech industry as a whole,” said David Grayzel, partner at Atlas Venture and founder and board director of Cadent Therapeutics. “We are thrilled to welcome Jodie to the Atlas team and look forward to the insights and experience she will bring to our portfolio.”
About Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.